Current status of pharmaceutical and genetic therapeutic approaches to treat DMD

Current status of pharmaceutical and genetic therapeutic approaches to treat DMD

Diğer sürümleri göster (1)

Duchenne muscular dystrophy (DMD) is a genetic disease affecting about one in every 3,500 boys. This X-linked pathology is due to the absence of dystrophin in muscle fibers. This lack of dystrophin leads to the progressive muscle degeneration that is often responsible for the death of the DMD patien...

Detaylı Bibliyografya
Asıl Yazarlar:	Pichavant, C, Aartsma-Rus, A, Clemens, P, Davies, K, Dickson, G, Takeda, S, Wilton, S, Wolff, J, Wooddell, C, Xiao, X, Tremblay, J
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	2011

Benzer Materyaller

Current status of pharmaceutical and genetic therapeutic approaches to treat DMD.
Yazar:: Pichavant, C, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Utrophin upregulation in DMD therapy: current status and new tools for the future
Yazar:: Fairclough, R, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

DMD antisense oligonucleotide mediated exon skipping efficiency correlates with flanking intron retention time and target position within the exon
Yazar:: Remko Goossens, ve diğerleri
Baskı/Yayın Bilgisi: (2023-12-01)

BMP antagonists enhance myogenic differentiation and ameliorate the dystrophic phenotype in a DMD mouse model
Yazar:: SongTing Shi, ve diğerleri
Baskı/Yayın Bilgisi: (2011-02-01)

DMD and West syndrome
Yazar:: Cardas, R, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Testing of SHIRPA, a mouse phenotypic assessment protocol, on Dmd(mdx) and Dmd(mdx3cv) dystrophin-deficient mice.
Yazar:: Rafael, J, ve diğerleri
Baskı/Yayın Bilgisi: (2000)

Targeting of CAT and VCAM1 as Novel Therapeutic Targets for DMD Cardiomyopathy
Yazar:: Bin Li, ve diğerleri
Baskı/Yayın Bilgisi: (2021-04-01)

Analysis of the transcriptional control of utrophin promoters as a therapeutic strategy for Duchenne muscular dystrophy (DMD).
Yazar:: Perkins, K, ve diğerleri
Baskı/Yayın Bilgisi: (2000)

A Potential New Therapeutic Approach to DMD: PKC Theta Inhibition
Yazar:: Maria Julia Marques
Baskı/Yayın Bilgisi: (2017-02-01)

Analysis of DMD translocations
Yazar:: Cockburn, D, ve diğerleri
Baskı/Yayın Bilgisi: (1991)

Second-generation compound for the modulation of utrophin in the therapy of DMD
Yazar:: Guiraud, S, ve diğerleri
Baskı/Yayın Bilgisi: (2015)

A multicenter comparison of quantification methods for antisense oligonucleotide-induced DMD exon 51 skipping in Duchenne muscular dystrophy cell cultures.
Yazar:: Monika Hiller, ve diğerleri
Baskı/Yayın Bilgisi: (2018-01-01)

Prime editing strategies to mediate exon skipping in DMD gene
Yazar:: Cedric Happi Mbakam, ve diğerleri
Baskı/Yayın Bilgisi: (2023-05-01)

Deletion of exons 45 to 55 in the DMD gene: from the therapeutic perspective to the in vitro model
Yazar:: Javier Poyatos-García, ve diğerleri
Baskı/Yayın Bilgisi: (2024-10-01)

Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals.
Yazar:: Koenig, M, ve diğerleri
Baskı/Yayın Bilgisi: (1987)

Novel 5 '-utrophin isoforms exhibit species-specific transcriptional profiles and provide additional candidates for therapeutic up-regulation in DMD
Yazar:: Perkins, K, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

P740: DMD or not DMD? Clinical genome sequencing in the interpretation of complex copy number gains
Yazar:: Edward Higginbotham, ve diğerleri
Baskı/Yayın Bilgisi: (2024-01-01)

Duchenne muscular dystrophy (DMD) cardiomyocyte-secreted exosomes promote the pathogenesis of DMD-associated cardiomyopathy
Yazar:: Melanie Gartz, ve diğerleri
Baskı/Yayın Bilgisi: (2020-11-01)

A novel canine model for Duchenne muscular dystrophy (DMD): single nucleotide deletion in DMD gene exon 20
Yazar:: Sara Mata López, ve diğerleri
Baskı/Yayın Bilgisi: (2018-05-01)

Networking to Optimize <i>Dmd</i> exon 53 Skipping in the Brain of <i>mdx52</i> Mouse Model
Yazar:: Mathilde Doisy, ve diğerleri
Baskı/Yayın Bilgisi: (2023-12-01)

Special Issue: Pathophysiology and Therapeutic Perspectives in DMD: The Well-Defined Role of the Immune System
Yazar:: Andrea Farini
Baskı/Yayın Bilgisi: (2021-12-01)

Improving translatability of preclinical studies for neuromuscular disorders: lessons from the TREAT-NMD Advisory Committee for Therapeutics (TACT)
Yazar:: Raffaella Willmann, ve diğerleri
Baskı/Yayın Bilgisi: (2020-02-01)

The analysis of DMD gene deletions by multiplex PCR in Indonesian DMD/BMD patients: the era of personalized medicine
Yazar:: Kristy Iskandar, ve diğerleri
Baskı/Yayın Bilgisi: (2019-10-01)

EXPLORING TRANSIENT, NEUTRONIC, REDUCED-ORDER MODELS USING DMD/POD-GALERKIN AND DATA-DRIVEN DMD
Yazar:: Elzohery Rabab, ve diğerleri
Baskı/Yayın Bilgisi: (2021-01-01)

A dinucleotide repeat polymorphism at the DMD locus.
Yazar:: Powell, J, ve diğerleri
Baskı/Yayın Bilgisi: (1991)

Generation and characterization of transgenic mice with the full-length human DMD gene.
Yazar:: 't Hoen, P, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Identification of serum protein biomarkers for utrophin based DMD therapy.
Yazar:: Guiraud, S, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Guidelines for Corticosteroid use in Treatment of DMD
Yazar:: Vamshi K. Rao
Baskı/Yayın Bilgisi: (2016-07-01)

Matrilineal analysis of mutations in the DMD gene in a multigenerational South Indian cohort using DMD gene panel sequencing
Yazar:: Arun Shastry, ve diğerleri
Baskı/Yayın Bilgisi: (2021-05-01)

Muscular dystrophy associated with the DMD gene in women
Yazar:: E. O. Vorontsova, ve diğerleri
Baskı/Yayın Bilgisi: (2024-09-01)

Measuring of customer satisfaction on example of Delta DMD
Yazar:: Kostić Ela
Baskı/Yayın Bilgisi: (2010-01-01)

Nanoparticles systemically biodistribute to regenerating skeletal muscle in DMD
Yazar:: Michael R. Hicks, ve diğerleri
Baskı/Yayın Bilgisi: (2023-08-01)

Bessel_DMD: the numerical code based on the scalar Fresnel–Kirchhoff integration to calculate the diffraction and bessel-like beam by using the DMD
Yazar:: Pei, Ting-Han, ve diğerleri
Baskı/Yayın Bilgisi: (2024)

Genetic characterization in symptomatic female DMD carriers: lack of relationship between X-inactivation, transcriptional DMD allele balancing and phenotype
Yazar:: Brioschi Simona, ve diğerleri
Baskı/Yayın Bilgisi: (2012-08-01)

Long-Read Sequencing Revealed Extragenic and Intragenic Duplications of Exons 56–61 in DMD in an Asymptomatic Male and a DMD Patient
Yazar:: Ying Bai, ve diğerleri
Baskı/Yayın Bilgisi: (2022-05-01)

Prime editing optimized RTT permits the correction of the c.8713C>T mutation in DMD gene
Yazar:: Cedric Happi Mbakam, ve diğerleri
Baskı/Yayın Bilgisi: (2022-12-01)

Tricyclo-DNA: A promising chemistry for the synthesis of antisense molecules for splice-switching approaches in DMD
Yazar:: Goyenvalle, A, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Embryonic myosin is a regeneration marker to monitor utrophin-based therapies for DMD
Yazar:: Guiraud, S, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Advancing the potential of peptide-PMO compounds in exon skipping therapy for DMD
Yazar:: Godfrey, C, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

A female patient carrying a novel DMD mutation with non-random X-chromosome inactivation from a DMD family
Yazar:: Ming-Xia Sun, ve diğerleri
Baskı/Yayın Bilgisi: (2024-02-01)